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Abstract 
Background: Elderly patients on haemodialysis have a high prevalence of polypharmacy and are at risk of drug-
related complications. More than 80 % of all prescribed drugs are metabolized by the cytochrome P450 (CYP) enzyme 
system. The aims of this study were to describe the prevalence of polymorphism in three CYP isoenzymes and the 
relationship between CYP polymorphism and prescribed drugs.
Methods: Fifty-one elderly haemodialysis patients aged ≥65 years were included. CYP-genotyping was carried out 
in whole blood by a real-time PCR method for detecting common variant alleles in CYP2C9, CYP2C19 and CYP2D6. The 
allele frequencies were calculated using the Hardy–Weinberg equation.
Results: The overall prevalence of CYP polymorphisms (heterozygous and homozygous) was 77 %. The prevalence 
of heterozygous carriers of variant alleles coding for defective CYP2D6, CYP2C9 and CYP2C19 was 64, 22 and 55 %, 
respectively; the prevalence of homozygous carriers was 6 % for each of the CYP2D6, CYP2C9 and CYP2C19 enzymes. 
The prevalence of the CYP2D6*6, CYP2D6*9 and CYP2D6*41 variant alleles did not differ (p = 0.31) from that in a Euro-
pean Caucasian reference population. Twenty-three patients (45 %) had at least one CYP mutation and used drugs 
that are metabolized by the CYP isoenzymes. Metoprolol and proton-pump inhibitors were the most commonly used 
drugs that could be affected by a heterozygous or homozygous mutation.
Conclusions: Polymorphisms of CYP2C9, CYP2C19 and CYP2D6 are common in elderly haemodialysis patients. Many 
of these patients have a phenotype with altered CYP enzyme activity and could benefit from close drug monitoring 
or a drug switch.
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Background
Patients with end-stage renal disease (ESRD) are treated 
with various medications for their kidney disease and 
associated comorbidities. The interindividual variability 
in drug response represents a clinical challenge. Factors 
such as age, smoking, fluid balance and other diseases 
influence drug effects (Samer et  al. 2013). In addition, 
genetic variations in the cytochrome P450 (CYP) enzyme 
system contribute to variability in drug response through 
altered metabolism. More than 80 % of all medications in 
use today are metabolized by the CYP enzyme system, 
which is a microsomal superfamily involved in the bio-
synthesis and degradation of endogenous compounds, 
chemicals, toxins and drugs (Trescot 2013). The most 
important enzymes for drug metabolism are CYP2C9, 
CYP2C19, CYP2D6 and CYP3A4.
The CYP2C9 enzyme partly determines warfa-
rin metabolism and activity, and patients with alleles 
CYP2C9*2 and CYP2C9*3 require lower doses to avoid 
bleeding (Aithal et  al. 1999; Samer et  al. 2013; Beyth 
et  al. 2000; Higashi et  al. 2002; Sanderson et  al. 2005). 
Therefore, a genotype-guided dosing of warfarin has 
been suggested (Pirmohamed et al. 2013). The CYP2C19 
enzyme metabolizes common drugs such as clopidogrel, 
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proton-pump inhibitors and antidepressants. The 
CYP2C19*2 and CYP2C19*3 alleles are associated with 
the clinical efficacy of clopidogrel (Umemura et al. 2008; 
Brandt et al. 2007), and hence also with the risk of cardio-
vascular events (Mega et al. 2010). The CYP2D6 enzyme 
is highly polymorphic and metabolizes various psycho-
tropic agents such as antidepressants, neuroleptics and 
opioids. The CYP2D6 poor metabolizer (PM) phenotype 
is associated with more frequent adverse drug reactions 
(Chen et  al. 1996; Chou et  al. 2000; Kirchheiner et  al. 
2004a, b) and varying responses to analgesics such as 
codeine, tramadol and oxycodone (Samer et al. 2010a, b; 
Brousseau et al. 2007).
The prevalence of mutations in these three CYP iso-
enzymes has not previously been reported for patients 
with ESRD. However, some studies have documented that 
chronic renal failure decreases drug metabolism by lower-
ing the activity in the CYP enzyme system by circulating 
uremic toxins, increased parathyroid hormone and mark-
ers of inflammation (Dreisbach and Lertora 2008; Guevin 
et al. 2002; Michaud et al. 2005, 2006; Renton 2004).
The aims of this study involving elderly haemodialysis 
patients were to (1) describe the prevalence of CYP poly-
morphisms, (2) measure the allele frequency of each CYP 
isoenzyme and (3) determine the prescribed medication 
for patients with altered enzyme activity through CYP 
polymorphisms.
Results
The characteristics of the 51 included patients and the 
most commonly used medications are given in Table  1. 
In all 47 (92 %) patients used medications metabolised by 
the CYP enzyme system; of whom 23 (45 %) had geneti-
cally altered metabolism via at least one of the tested 
CYP isoenzyme.
In total, 64 and 6 % of the patients were heterozygous 
and homozygous carriers of variant alleles encoding 
defective CYP2D6, respectively; these corresponding 
proportions for the alleles encoding defective CYP2C9 
were 22 and 6  %, and for the alleles encoding defective 
CYP2C19 they were 55 and 6  %. Of the 51 patients, 39 
(77 %) had one or more CYP enzyme defects, defined as 
either heterozygous or homozygous. Furthermore, 16 
patients (31 %) had two CYP defects (Table 2).
The frequencies of the CYP2C9*1, CYP2C9*2, CYP2C9*3, 
CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17, 
CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, 
CYP2D6*9, CYP2D6*10 and CYP2D6*41 alleles in the 
haemodialysis population are presented in Table  3. The 
CYP2D6 enzyme was highly polymorphic. The most 
frequent inactive allele was CYP2D6*4, followed by 
CYP2D6*5, CYP2D6*3 and CYP2D6*6. Although the 
CYP2D6*6, CYP2D6*9 and CYP2D6*41 alleles appeared 
to be more common in the present study population than 
among European Caucasians, the difference was not statis-
tically significant (p = 0.31).
Most patients (47 %) were identified as IM, followed by 
PM (8 %). Nine single drugs and drugs belonging to two 
other drug classes were being used by IM or PM patients 
for all three CYP isoenzymes. Metoprolol was the most 
prevalent drug among the PMs and IMs of CYP2D6, 
while proton-pump inhibitors were the most frequently 
used among those for CYP2C19 (Table 4).
Discussion
To the best of our knowledge, this study is the first 
to identify the prevalence of three CYP isoenzymes 
(CYP2C9, CYP2C19 and CYP2D6) and their allele fre-
quencies in an elderly haemodialysis population, and the 
first to determine the relationship between homozygous 
and heterozygous mutations of all CYP isoenzymes and 
prescribed medications.
Table 1 Characteristics of the study population (n = 51)
Except where stated otherwise, the data are number (%)
a Post-renal disease = hydronephrosis, kidney stone disease, retroperitoneal 
fibrosis
b Other = kidney cancer, loss of kidney graft, amyloidosis, poisioning, 
antiglomerular basement membrane nephritis
c ACE inhibitor = angiotensin-converting enzyme inhibitor
Gender, male 39 (77)
Age, years, median (range) 74 (65‒89)
Charlson comorbidity index, median (range) 5 (2–9)
Time in haemodialysis, months, median (range) 8 (0–108)
Urea clearance, Kt/V 1.47 ± 0.29
Arteriovenous fistula 29 (57)




Diabetic nephropathy 7 (14)




Diuretic drugs 38 (75)
Statins 31 (61)
Beta-blockers 29 (57)
Proton-pump inhibitors 19 (37)
Analgesics 17 (34)
ACE inhibitorc/angiotensin II receptor antagonist 14 (28)
Warfarin 11 (22)
Benzodiazepines 7 (14)
Tricyclic antidepressants 3 (6)
Number of medications, median (25th–75th percentile) 13 (12–14)
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The main finding of this study was the high prevalence 
(77  %) of genetic polymorphisms of three CYP isoen-
zymes. This finding is in line with a previous report of a 
high prevalence of the same three CYP isoenzymes in a 
high-opioid-use population (Tennant 2012) (although 
this was in a completely different population). However, 
to the best of our knowledge there is a dearth of preva-
lence studies for CYP polymorphisms in most common 
chronic diseases. This is the first study of haemodialysis 
patients using this approach.
The frequencies of the CYP2C9, CYP2C19 and CYP2D6 
alleles have been reported elsewhere for various popula-
tions (Waade et al. 2014; Molden et al. 2002; Swen et al. 
2012; Mega et  al. 2011; Tamura et  al. 2011). CYP2D6*3, 
CYP2D6*4, CYP2D6*5 and CYP2D6 *6 are known to be 
inactive alleles, and the CYP2D6*4 allele is the most com-
mon (Bradford 2002; Gaedigk et  al. 1999). These four 
inactive alleles accounted for 29 % of the CYP2D6 alleles 
in the present study, which is comparable with a percent-
age of 26  % reported for a European general population 
(Bradford 2002). The proportion of PMs in the elderly 
haemodialysis population in the present study is com-
parable with those reported previously (Bradford 2002; 
McGraw and Waller 2012). However, the CYP2D6*6 and 
Table 2 Polymorphisms of  the CYP enzymes CYP2C9, 
CYP2C19 and CYP2D6 (n = 51)
95 % CI = 95 % confidence interval




95 % CI,  
 %
CYP2C9 Normal *1/*1 37 (73) 58–84
Intermediate *1/*2, *1/*3 10 (20) 11–35
Poor *2/*2, *2/*3,*3/*3 4 (8) 1–16
CYP2C19 Normal *1/*1 20 (39) 26–54
Approximately 
normal
*1/*17, *2/*17 18 (35) 22–50
Intermediate *1/*2,*1/*3 10 (20) 9–33
Poor *2/*2 2 (4) 0–13
Increased *17/*17 1 (2) 0–10
CYP2D6 Normal *1/*1 13 (26) 14–40
Approximately 
normal
*1/*9, *1/*41 10 (20) 10–33
Intermediate *1/*3, *1/*4, *1/*5, 




Poor *3/*4, *4/*4, *4/*5, 
*5/*6
4 (8) 2–19
Table 3 Frequencies of CYP2C9, CYP2C19 and CYP2D6 vari-
ant alleles in  the haemodialysis patients, and  population 
reference values
a Data from McGraw et al. (McGraw and Waller 2012)













CYP2C9 Normal 1a 82 74–91 78–86
Decreased 2a 8 2–14 8–15
3a 10 3–16 1–8
CYP2C19 Normal 1a 59 48–69 87
Decreased 2a 21 13–28 13
3a 0 0–3 0
Increased 17a 20 12–27 20
CYP2D6 Normal 1a 54 45–63 33–84
None 3a 2 0–5 0–3
4a 21 13–28 11–29
5a 4 0–8 1–7
6a 2 0–5 1–2
Decreased 9a 4 0–9 0–3
10a 3 0–7 1–6
41a 11 5–16 8–10b
Table 4 Activity of  CYP enzymes and  prescribed drugs 
potentially influenced by CYP polymorphisms (n = 51)
CYP enzyme Enzyme activity Drug Number
CYP2C9 Intermediate (n = 11) Warfarin 1
Losartan 1
Poor (n = 3) Warfarin 1
CYP2C19 Intermediate (n = 10) Proton-pump inhibitor 4
Diazepam 1
Poor (n = 2) Proton-pump inhibitor 1
Diazepam 1
Increased (n = 1) Escitalopram 1
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CYP2D6*9 alleles were more prevalent in the present pop-
ulation than in Caucasian and in Central and South Amer-
ican Indian populations (Bradford 2002; Jorge et al. 1999; 
Marez et al. 1997; Griese et al. 1998; Gaedigk et al. 1999; 
Sachse et al. 1997). The previously reported frequencies of 
the CYP2C19*2, CYP2C19*3 and CYP2C19*17 alleles are 
similar to those reported here (Rudberg et  al. 2008; Sim 
et al. 2006; Kurzawski et al. 2006).
A study involving non-institutionalized patients aged 
>60 years found that medications metabolized by CYP 
systems were used by 62  % of patients (Cabrera et  al. 
2009), versus 92 % in the present study. Elderly patients 
are known to be exposed to higher drug concentrations 
for a given dose compared to younger adults (Waade 
et  al. 2012), due to multiple factors such as reduc-
tions in hepatic blood flow, cardiac output and renal 
function. Both renal failure and genetically reduced 
or absent enzyme activity increase the vulnerability 
to side effects. A recent report confirmed the effects 
of age on exposure to antidepressants in patients with 
the CYP2C19 and CYP2D6 PM genotypes (Waade et al. 
2014).
This study was subject to some limitations. First, 
there was no comparator healthy control group of 
elderly subjects, which would have enabled a better 
understanding of the genetic variation of the three CYP 
isoenzymes and their allele frequencies. Second, as no 
measurements of drug levels were performed to inves-
tigate the effect of altered CYP isoenzymes on the elim-
ination of the drugs, the study was unable to show the 
practical impact of these polymorphisms in this popu-
lation. Finally, most of the study patients were Euro-
pean Caucasians, hence limiting the generalizability of 
the findings.
In general, the use of pharmacogenetic testing in 
clinical settings has the potential to improve patient 
outcomes and the long-term cost of care through reduc-
tion of polypharmacy and risk of drug-related problems 
(Dorfman et al. 2013), although the practical implications 
of detected CYP enzyme polymorphism are not yet clear. 
Some studies including CYP genotyping have provided 
useful information about medication dosages, or have 
led to changes in treatments (Pirmohamed 2014; Molden 
et al. 2002; Mega et al. 2011; Pettersen et al. 2011). The 
US Food and Drug Administration has published a list 
of nearly 100 drugs with a recommendation for genetic 
testing (FDA 2014). Similarly, the Dutch Pharmaco-
genetics Working Group guidelines recommend dose 
adjustments in 5–10  % of drugs prescribed to patients 
with altered CYP2D6 and CYP2C19 metabolism, and 
increased awareness for an adverse drug response in all 
these patients (Swen et  al. 2012). Thus, the finding of a 
CYP enzyme abnormality does not necessarily require 
dose adjustment.
Conclusions
In conclusion, a high prevalence of three CYP isoenzymes 
was found in elderly haemodialysis patients at the level of 
the general population. About 45  % of these patients had 
one or more mutations in their CYP isoenzymes and used 
medications for which the metabolism may be affected by 
such mutations. These patients may benefit from close drug 
monitoring or a drug switch. The actual impact of these 
mutations on drug serum levels is a topic for future studies.
Methods
Study population and data collection
This study was performed between July and Decem-
ber 2012 in the dialysis centre at Akershus University 
Hospital, Norway. This hospital has a catchment area 
comprising about 480,000 inhabitants. Of the 102 hae-
modialysis patients screened at the start of the study, 
52 were ≥65 years of age and eligible for inclusion. One 
patient died before assessment; the remaining 51 patients 
participated in the study.
The following patient data were collected via review 
of their medical records: medical history, comorbidities 
(evaluated using the Charlson comorbidity index), dialy-
sis treatment quality index (quantified in units of Kt/V), 
haemodialysis access and medication history. Blood sam-
ples were drawn at the start of dialysis treatment on the 
day of a regularly scheduled haemodialysis session.
Our institute ethical committee evaluated the study 
protocol and approved the study. All participants gave 
their consent at the start of the study.
Genotyping of CYP enzymes
Venous blood samples (with EDTA as anticoagulant) 
were genotyped at the Centre for Psychopharmacol-
ogy, Diakonhjemmet Hospital, Norway. A real-time 
PCR method was applied using mutation-specific 
TaqMan probes (Life Technologies, Foster City, CA, 
USA) (Schaeffeler et  al. 2003). Genomic DNA was 
extracted instrumentally from leukocytes prior to apply-
ing the PCR using a MagNA Pure LC DNA Isolation 
Kit I (Roche Diagnostics, Oslo, Norway). The genotyp-
ing assay included detection of the single-nucleotide 
polymorphisms specific for the following variant alleles: 
CYP2C9*2 and CYP2C9*3; CYP2C19*2, CYP2C19*3, 
CYP2C19*4 and CYP2C19*17; and CYP2D6*3, 
CYP2D6*4, CYP2D6*6, CYP2D6*9, CYP2D6*10 and 
CYP2D6*41. In addition, copy-number analyses was 
implemented to establish the presence of CYP2D6 gene 
deletion (CYP2D6*5) or multiplication. The absence of 
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mutated alleles was interpreted as the presence of the 
functional wild-type allele (CYP2D6*1). The genotyping 
assay did not discriminate between functional and non-
functional CYP2D6 multiplications.
Classification of enzyme activity
A genotype-predicted phenotype was assigned to each 
patient. For CYP2D6, intermediate metabolizers (IMs) 
were defined as patients carrying two reduced-activ-
ity alleles (CYP2D6*9, CYP2D6*10 and CYP2D6*41) 
or carrying one inactive allele (CYP2D6*3, CYP2D6*4, 
CYP2D6*5 and CYP2D6*6). Poor metabolizers (PMs) 
were defined as patients carrying two inactive alleles 
(CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*6). For 
CYP2C19 and CYP2C9, IMs were defined as patients 
with one inactive allele (CYP2C19*2, CYP2C19*3, 
CYP2C9*2, and CYP2C9*3), while PMs were defined as 
patients carrying two inactive alleles.
Statistical analyses
Descriptive statistics are presented as median (range or 
25th–75th percentiles) or number (%) values as appro-
priate. The allele frequencies were calculated using the 
Hardy–Weinberg equation and compared to published 
general population references for European Caucasians 
(McGraw and Waller 2012). Groups were compared using 
Fisher’s exact test. All analyses were carried out using 
SPSS statistical software (version 19, IBM, SPSS, Chicago, 
IL, USA). The threshold for statistical significance was set 
at p < 0.05 (two-sided tests). The study was approved by 
the privacy ombudsman of Akershus University Hospital.
Abbreviations
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